Who is missing from SGLT-2 inhibitor trials? Implications for drug safety and generalizability: a systematic review and meta-analysis

Authors

Institutions

Publication Details

Journal
Expert Opinion on Drug Safety
Published
2026-03-05
DOI
https://doi.org/10.1080/14740338.2026.2641874
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Who is missing from SGLT-2 inhibitor trials? Implications for drug safety and generalizability: a systematic review and meta-analysis

Flory Tsobo Muanda, Mohammad Ali Omrani, Fatemeh Ahmadi, Hasti Sadeghi et al.
Expert Opinion on Drug Safety
Diabetes Treatment and Management
article

Who is missing from SGLT-2 inhibitor trials? Implications for drug safety and generalizability: a systematic review and meta-analysis

Flory Tsobo Muanda, Mohammad Ali Omrani, Fatemeh Ahmadi, Hasti Sadeghi, Azar Jafari, Lujain Ez Eddin, Bala Swetha Baskaran
article en

Abstract

No abstract available for this paper.
Expert Opinion on Drug Safety
Western University (CA), London Health Sciences Centre (CA)
Good health and well-being
Openalex Percentile: Top 34%
Diabetes Treatment and Management
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.